Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of Carfilzomib-Associated Cardiac Adverse Events.

Clinical lymphoma, myeloma & leukemia - 1 May 2016

Mikhael Joseph

Abstract excerpt

Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens. This article...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiotoxicity
Share to Clinical Trials, Phase I as Topic
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Disease Management

Share to Heart Diseases

Share to Multiple Myeloma

Share to Proteasome Inhibitors

Source

Identifiers

PMID: 26907720
DOI: 10.1016/j.clml.2016.01.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of Carfilzomib-Associated Cardiac Adverse Events.PMID 26907720Read ↗

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agentsSemantic proximity Read ↗

Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.Semantic proximity Read ↗

Case Report: Fatal myocarditis after combination of immune checkpoint inhibitor and platinum doublet chemotherapySemantic proximity Read ↗

Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysisSemantic proximity Read ↗

Thrombotic microangiopathy associated with proteasome inhibitorsSemantic proximity Read ↗

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular ManagementSemantic proximity Read ↗

Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patientsSemantic proximity Read ↗

Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan.Semantic proximity Read ↗

Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker.Semantic proximity Read ↗

Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.Semantic proximity Read ↗

Use of milrinone to support therapy-induced heart failure through hematopoietic stem cell transplantation in a pediatric patient with high-risk FLT3+ acute myeloid leukemia.Semantic proximity Read ↗

Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.